EP1.14-46 The KIF5B-RET Fusion as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.08.2331 ◽

2019 ◽

Vol 14 (10) ◽

pp. S1049

Author(s):

Y. Zhu ◽

W. Wang ◽

C. Xu ◽

Q. Zhang ◽

W. Zhuang ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Inhibitor Resistance

Download Full-text

Epigenetic Reprogramming Driven By Metabolic Alterations As A Mechanism Of EGFR – Tyrosine Kinase Inhibitor Resistance In Human Lung Adenocarcinoma

The FASEB Journal ◽

10.1096/fasebj.2020.34.s1.00602 ◽

2020 ◽

Vol 34 (S1) ◽

pp. 1-1

Author(s):

Abhilash Venugopalan ◽

Khoa Nguyen ◽

Matthew Lynberg ◽

Tapan Maity ◽

Yue Qi ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Metabolic Alterations ◽

Human Lung Adenocarcinoma ◽

Egfr Tyrosine Kinase ◽

Inhibitor Resistance

Download Full-text

Abstract 1836: Erlotinib induces NF-kappa B dependence that promotes EGFR tyrosine kinase inhibitor resistance in lung adenocarcinoma

10.1158/1538-7445.am2014-1836 ◽

2014 ◽

Author(s):

Collin M. Blakely ◽

Evangelos Pazarentzos ◽

Saurabh Asthana ◽

Victor Olivas ◽

Irena Tan ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Inhibitor Resistance

Download Full-text

The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma

Clinical Lung Cancer ◽

10.1016/j.cllc.2018.09.011 ◽

2019 ◽

Vol 20 (1) ◽

pp. e73-e76 ◽

Author(s):

You-cai Zhu ◽

Wen-xian Wang ◽

Qu-xia Zhang ◽

Chun-wei Xu ◽

Wu Zhuang ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Gene Mutation ◽

Kinase Inhibitor ◽

Fusion Gene ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Inhibitor Resistance

Download Full-text

Abstract 1756: Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma

10.1158/1538-7445.am2014-1756 ◽

2014 ◽

Author(s):

Hui-Yi Shiao ◽

Tsu-An Hsu ◽

Wen-Hsing Lin ◽

Tsong-Toh Yang ◽

Hui-Fang Hsieh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma

10.1186/s12885-018-5116-9 ◽

2018 ◽

Vol 18 (1) ◽

Author(s):

Eun Young Kim ◽

Arum Kim ◽

Gaeun Lee ◽

Hangsuck Lee ◽

Yoon Soo Chang

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma

Translational Lung Cancer Research ◽

10.21037/tlcr-20-893 ◽

2021 ◽

Vol 10 (2) ◽

pp. 699-711

Author(s):

Minsu Kang ◽

Changhee Park ◽

Se Hyun Kim ◽

Sock Won Yoon ◽

Koung Jin Suh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Expression Level ◽

Egfr Tyrosine Kinase Inhibitor ◽

Programmed Death Ligand 1 ◽

Egfr Tyrosine Kinase ◽

Programmed Death

Download Full-text

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

10.18632/oncotarget.7189 ◽

2016 ◽

Vol 7 (11) ◽

pp. 12404-12413 ◽

Author(s):

Shang-Gin Wu ◽

Yi-Nan Liu ◽

Meng-Feng Tsai ◽

Yih-Leong Chang ◽

Chong-Jen Yu ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Predictive value of serum HGF for treatment response to EGFR tyrosine kinase inhibitor in patients with lung adenocarcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7563 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7563-7563

Author(s):

K. Kasahara ◽

T. Arao ◽

K. Sakai ◽

A. Sakai ◽

T. Sone ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Treatment Response ◽

Predictive Value ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations

Molecular and Clinical Oncology ◽

10.3892/mco.2018.1550 ◽

2018 ◽

Author(s):

Ming‑Szu Hung ◽

Yu‑Hung Fang ◽

Yu‑Ching Lin ◽

Jr‑Hau Lung ◽

Meng‑Jer Hsieh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Associated Factors ◽

Kinase Inhibitor ◽

Egfr Mutations ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Correlation between Efficacy of the EGFR Tyrosine Kinase Inhibitor and Serum Tumor Markers in Lung Adenocarcinoma Patients

Clinical Laboratory ◽

10.7754/clin.lab.2013.131002 ◽

2014 ◽

Vol 60 (09/2014) ◽

Author(s):

Jin Pan ◽

Yu Hou ◽

Guo Zhang

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Tumor Markers ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Serum Tumor Markers ◽

Egfr Tyrosine Kinase

Download Full-text